ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 109

Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

Mei-Sing Ong1, Gordon Schiff 2 and Marc Natter 3 for the CARRA investigators, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, 2Harvard Medical School, Boston, 3Boston Children's Hospital, Boston

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Clinical practice, differential diagnosis, joint damage, juvenile idiopathic arthritis (JIA), outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Session 2

Session Type: ACR Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly characterized, with no recently published data on such delays in JIA cohorts in North America. We analyzed the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry to examine diagnostic delays in JIA, factors associated with delays, and impact of delays on select outcomes.

Methods: We performed a retrospective analysis of the CARRA Registry JIA cohort, focusing on subjects with new onset JIA who were enrolled in the registry within 6 months of JIA diagnosis and followed for ≥12 months (n=1195, enrollment years 2015-2018). We developed generalized linear models to identify factors associated with diagnostic interval (defined as the interval from self-reported symptom onset to physician-diagnosed JIA) and logistic regression models to examine the impact of this interval on risks of (1) radiographic evidence of joint damage and (2) progression to >4 joints involvement (polyarticular-course JIA).

Results: The median and mean time from symptom onset to JIA diagnosis were 3 months and 6.7 months, respectively. 31% of subjects (n=370) were diagnosed ≥6 months after symptom onset and 16% (n=189) were diagnosed ≥1 year after symptom onset (Table 1). As expected, diagnostic interval strongly correlated with duration from symptom onset to first pediatric rheumatology visit. Subjects with systemic JIA (sJIA) experienced shorter diagnostic intervals (OR 0.45; 95% CI 0.35-0.58; p< 0.001); longer intervals were observed among those with enthesitis-related arthritis (OR 1.78; 95% CI 1.41-2.29; p< 0.001) and undifferentiated JIA (OR 2.20; 95% CI 1.40-3.74; p=0.002). Older children, males, and individuals of black race experienced longer intervals (Table 2).   Higher risk of development of radiographic joint damage was associated with longer diagnostic intervals (OR 1.06; 95% CI 1.04-1.09; p< 0.001). The risk persisted after adjusting for JIA subtype (OR 1.04; 95% CI 1.01-1.06; p=0.006), age, and sex. Longer diagnostic interval was also associated with a higher risk of polyarticular course at presentation (OR 1.07; 95% CI 1.03-1.10; p< 0.001) and persisted after adjusting for JIA subtype. When all subjects with JIA, i.e. not only thosewith new onset JIA at enrollment, were analyzed (n=3719), a diagnostic interval of ≥12 months (n=525) was associated with an increased risk (OR 1.09; 95% CI 1.04-1.15; p< 0.001) of radiographic joint damage in comparison to a diagnostic interval of 0-2 months, after adjusting for age, sex, and JIA subtype. This risk was greatest for sJIA (OR 1.34; 95% CI 1.03-1.72; p=0.028).

Conclusion: Individuals with JIA frequently experience intervals of months to years from symptom onset to initial diagnosis; these delays correlate with subsequent radiographic joint damage, an objective, long-term adverse outcome. While we acknowledge limitations of self-report of symptom onset and non-uniformity  in obtaining joint radiographs, we believe our results nonetheless highlight the need for improvements in early recognition and referral of patients with suspected JIA to pediatric rheumatology care.

Figure 1

Figure 2


Disclosure: M. Ong, None; G. Schiff, None; M. Natter, None.

To cite this abstract in AMA style:

Ong M, Schiff G, Natter M. Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/incidence-contributing-factors-and-impact-of-diagnostic-delay-in-juvenile-idiopathic-arthritis-analysis-of-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-contributing-factors-and-impact-of-diagnostic-delay-in-juvenile-idiopathic-arthritis-analysis-of-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology